The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target to support with the development of future first-in-class ADCs.

With sessions led by Almac Discovery, AstraZeneca, Bolt Biotherapeutics, and many other industry leaders, leave this meeting equipped to perform a strategic evaluation of when and how to approach developing an ADC against a novel target. Enhance this knowledge with exclusive insight from brand-new biotechs, Epifold and GO Therapeutics striving to leave their mark on the ADC field by sharing their innovative strategy which has reaped success in novel ADC targeting.

Don’t miss this opportunity to join an audience of 80+ highly focused biologists, discovery researchers, computational biologists and bioinformaticians, as well as senior C-level and Alliance Management experts. End your 2024 ADC conference calendar with the perfect balance of scientific and strategic level conversations and gain the know-how to invigorate your target selection strategy and propel more ADCs to first-in-class therapeutics.

View all the industry strategies, innovation sessions and networking opportunities in the FREE event guide here: https://ter.li/un31n9